Why Venezuela Is Emerging as a Top Destination for First-in-Human Clinical Trials
Venezuela offers treatment-naïve populations, 60,000+ physicians, the region's lowest costs, and fast enrollment — making it a strategic destination for first-in-human trials.
June 5, 2026
15
min read
By
bioaccess® Editorial Team
first-in-human clinical trial Venezuela
Venezuela FIH destination
clinical trials Latin America
treatment-naive populations
FIH CRO Venezuela
**Key Takeaways**
- • Treatment-naïve populations: Ideal for novel drug and device evaluation with clean baselines
- • 60,000+ physicians: Large pool of GCP-trained investigators with international experience
- • 40-60% cost savings: Lowest operational costs in Latin America
- • Fast enrollment: High disease prevalence and eager patient populations
- • bioaccess® FIH guarantee: The first and only FIH-focused CRO operating in Venezuela
Venezuela's emerging FIH opportunity
In the global landscape of first-in-human clinical trials, Venezuela is emerging as one of the most compelling new destinations. While the country is less frequently discussed than established LATAM research markets like Mexico, Colombia, or Brazil, Venezuela offers a unique combination of strategic advantages that make it particularly attractive for FIH and early-phase studies.
As the third-largest medical device market in Latin America, Venezuela has the patient populations, clinical infrastructure, and physician talent to support complex clinical trials — at a fraction of the cost of traditional markets. bioaccess® is the first CRO to establish clinical trial operations in Venezuela, bringing its specialized FIH expertise to this underserved but high-potential market.
Treatment-naïve patient populations: a clean baseline for FIH
One of Venezuela's most significant advantages for FIH trials is access to treatment-naïve patient populations. Due to limited access to newer therapies available in the US and Europe, many Venezuelan patients have not been exposed to standard-of-care treatments, creating exceptionally clean baselines for evaluating novel compounds and devices.
For first-in-human studies, treatment-naïve populations offer:
- Cleaner pharmacokinetic and pharmacodynamic profiles without drug-drug interactions
- More pronounced and measurable treatment effects
- Reduced confounding from prior therapy exposure
- Better signal detection for safety and efficacy endpoints
- Higher enrollment rates due to unmet medical needs
60,000+ trained physicians: a deep talent pool
Venezuela's medical education system has historically been one of the strongest in Latin America, producing over 60,000 active physicians. Many Venezuelan doctors received training at internationally recognized institutions and maintain current GCP certifications.
The physician workforce includes specialists across virtually every therapeutic area, from cardiology and oncology to neurology and rare diseases. bioaccess® has identified and pre-qualified investigators across multiple specialties and cities, creating a ready-to-activate network for sponsors.
40-60% cost savings vs. traditional markets
Venezuela offers the lowest operational costs in Latin America — and by extension, among the lowest globally. Sponsors can expect 40-60% savings compared to conducting the same trial in the US or Europe.
| Cost Category | US / EU Benchmark | Venezuela | Savings |
|---|---|---|---|
| Per-patient cost (Phase I) | $50,000-$100,000 | $20,000-$40,000 | 50-60% |
| Site fees (annual) | $100,000-$200,000 | $30,000-$80,000 | 60-70% |
| Investigator fees | $15,000-$25,000/site | $5,000-$12,000/site | 50-65% |
| Monitoring costs | $5,000-$8,000/visit | $2,000-$4,000/visit | 50-60% |
| Regulatory submissions | $50,000-$150,000 | $15,000-$40,000 | 60-70% |
Bilingual investigators and research staff
A significant practical advantage of Venezuela for US-based sponsors is the prevalence of bilingual (Spanish-English) investigators and study staff. Many Venezuelan physicians completed fellowships or advanced training in the United States, making communication with sponsors seamless.
This bilingual capability streamlines:
- Sponsor-investigator meetings and study training sessions
- Protocol interpretation and implementation
- Safety reporting and medical monitoring communications
- FDA interaction preparation and data package development
- Manuscript preparation and conference presentations
Fast enrollment potential
Venezuela's combination of high disease prevalence, treatment-naïve populations, and patient eagerness to access innovative therapies creates conditions for rapid clinical trial enrollment. In many therapeutic areas, enrollment in Venezuela can be 30-50% faster than in the US or Europe.
**Enrollment acceleration**
For sponsors who have experienced slow enrollment in US or European sites, adding Venezuelan sites through bioaccess® can dramatically accelerate overall program timelines. Venezuela's large, underserved patient populations are highly motivated to participate in clinical trials, particularly for conditions where local treatment options are limited.
INHRR regulatory framework
Venezuela's regulatory authority, INHRR (Instituto Nacional de Higiene Rafael Rangel), oversees clinical trial authorization. The INHRR follows international standards and the approval process takes approximately 3-6 months. For detailed guidance on the INHRR approval process, see our complete regulatory guide.
Medical device registration through SACS offers an exceptionally fast ~20 business day timeline, making Venezuela attractive for market access alongside clinical research.
bioaccess® FIH guarantee in Venezuela
bioaccess® offers a unique FIH guarantee for sponsors choosing Venezuela: if regulatory approval timelines exceed our projections, bioaccess® absorbs the additional operational costs. This risk-sharing model reflects our confidence in our Venezuelan operations and our commitment to sponsor success.
- First CRO to establish clinical trial operations in Venezuela
- Pre-qualified investigator network across Caracas, Valencia, Maracaibo, and Barquisimeto
- End-to-end regulatory support from INHRR submission to site activation
- Risk-sharing operational model unique in the CRO industry
- 50+ medtech companies supported across Latin America
Case examples: FIH success stories from bioaccess®
While bioaccess®'s Venezuelan operations are the newest addition to our LATAM network, our track record across the region demonstrates the model:
- Supira Medical: FIH in Paraguay — 70+ patients, zero complications, now in US pivotal trial
- Ocumetics Technology: FIH bioelectronic lens trial in Mexico — positive 3-month results
- enVVeno Medical: bioaccess® supported early first-in-human clinical work in Colombia; enVVeno's non-surgical enVVe® System received the first-ever FDA IDE approval for a U.S. pivotal study (TAVVE®) on April 29, 2026 (IDE authorizes the STUDY, not device approval)
- Unravel Biosciences: Proof-of-concept in Colombia — first RTT/PTHS trials in Latin America
**Ready to explore Venezuela for your FIH trial?**
bioaccess® is the FIH-focused CRO with operations in Venezuela. Contact us to discuss your clinical program, or take our Pre-FIH Assessment to evaluate your readiness.
Frequently asked questions
Launch your FIH trial in Venezuela with bioaccess®
The FIH-focused CRO, now operating in Venezuela — Latin America's most cost-effective clinical trial destination.
Get your FIH roadmap
View case studies